Newsletter Signup – Under Article \/ In Page<\/p>\n
“*” indicates required fields<\/p>\n
Genetic diseases are often among the most clearly defined in terms of their molecular origin, but developing treatments for them remains a challenge for biotech companies. Many of these conditions are rare, severe, and underdiagnosed, leaving patients with limited or no therapeutic options.<\/strong>\u00a0\u00a0<\/p>\n In this article, we focus on companies that have raised funding rounds in the past two years to advance treatments for genetic diseases.\u00a0\u00a0<\/p>\n Actio Biosciences\u00a0<\/p>\n Actio Biosciences focuses on rare neurological conditions caused by well-characterized mutations, such as severe childhood epilepsy driven by KCNT1 gene variants and hereditary neuropathies linked to TRPV4. Its pipeline is rooted in a proprietary platform called the Rare Disease Target Atlas.\u00a0<\/p>\n ABS\u20111230, one of the company\u2019s two lead programs, targets KCNT1, a potassium channel whose gain-of-function mutations can result in excessive neuronal firing and early-onset, drug-resistant epilepsy. Actio\u2019s molecule is designed to selectively inhibit the overactive channel without affecting its normal physiological role.\u00a0\u00a0<\/p>\n Its second lead asset, ABS\u20110871, is a TRPV4 inhibitor in development for CMT2C. This form of Charcot\u2013Marie\u2013Tooth disease<\/a> is caused by mutations that render the TRPV4 calcium channel hyperactive, leading to nerve degeneration. ABS\u20110871 is designed to normalize calcium flow and has shown positive effects on motor function and neural integrity in preclinical studies.\u00a0<\/p>\n In June 2025, Actio raised<\/a> a $66 million series B round co-led by Regeneron Ventures and Deerfield Management. ABS\u20110871 began<\/a> dosing in healthy volunteers earlier this year, and the company expects to launch a phase 1b trial in 2026.\u00a0\u00a0<\/p>\n AIRNA Therapeutics\u00a0<\/p>\n AIRNA Therapeutics emerged in 2021 from research on ADAR-mediated RNA editing. The company\u2019s mission is to create precise, reversible \u201cRNA cures\u201d that can fix disease-causing mutations, or even mimic beneficial genetic variants using oligonucleotides designed to recruit the body\u2019s own RNA-editing machinery.\u00a0<\/p>\n AIR\u2011001, the flagship program, targets the PiZ mutation in the\u202fSERPINA1\u202fgene responsible for AATD. This condition leads to defective alpha\u20111 antitrypsin protein, which accumulates in the liver and fails to protect the lungs. Rather than replace the protein, AIR\u2011001 goes straight to the RNA transcript, converting the mutant adenosine to inosine, restoring production of the normal protein.\u00a0\u00a0<\/p>\n The fresh funding from the $155 million series B<\/a> supports the upcoming investigational new drug (IND) filing and phase\u202f1\/2 trial expected this year. Beyond AATD, AIRNA is building a pipeline aimed at both rare and common diseases, some designed to repair damage, others to confer beneficial traits, like enhanced cardiometabolic resilience.\u00a0<\/p>\n Alesta Therapeutics\u00a0<\/p>\n Founded in late 2021, Alesta Therapeutics is a rare disease-focused biotech operating between Leiden and Boston. The company is developing orally available small-molecule therapies that target genetic disorders lacking effective treatment options. In the company\u2019s pipeline, two candidates stand out.\u00a0<\/p>\n ALE1, an orally active inhibitor in-licensed from 1cBio, aims to treat hypophosphatasia (HPP), a debilitating condition caused by ALPL mutations leading to excess inorganic pyrophosphate (PPi), weak bones, and early tooth loss. By reducing PPi levels in preclinical models, ALE1 has demonstrated potential to treat the full clinical spectrum of HPP and is expected to begin clinical testing in late 2025.\u00a0<\/p>\n Meanwhile, ALE2 targets a subset of Charcot\u2013Marie\u2013Tooth disease caused by mutations in tRNA synthetases. It inhibits the GCN2 kinase, a key sensor of ribosomal stress, to reduce neurotoxicity and preserve nerve function.\u00a0<\/p>\n The \u20ac65 million ($70 million)\u202fseries A<\/a>, led by Frazier Life Sciences and Droia Ventures with support from Novartis Venture Fund and others, validated Alesta\u2019s approach.\u00a0<\/p>\n Azafaros\u00a0<\/p>\n Azafaros\u2019 objective is to develop brain-penetrant, oral small-molecule therapies that modify disease progression in rare lysosomal storage disorders, conditions marked by the accumulation of toxic substances in the brain and peripheral tissues. These incurable, neurological genetic diseases, such as NPC and gangliosidoses, are typically lethal and lack effective treatment options.\u00a0<\/p>\n Its lead asset, nizubaglustat, is a dual-acting azasugar designed to inhibit two key glycosylation enzymes involved in lipid buildup. By restoring lipid homeostasis, it aims to slow or halt neurodegeneration.\u00a0\u00a0<\/p>\n Nizubaglustat has already moved through phase\u202f2, with topline data recently released showing<\/a> positive pharmacokinetics, safety, and signs of metabolic correction in patients. The \u20ac132 million ($155 million) series B<\/a> will fund two pivotal phase\u202f3 trials in NPC and GM1\/GM2, set to begin later this year.\u00a0<\/p>\n Beacon Therapeutics\u00a0<\/p>\n Beacon Therapeutics is developing gene therapies for inherited retinal diseases<\/a>, with a focus on conditions that cause progressive vision loss and currently lack effective treatments. Its lead program, laru\u2011zova, also known as AGTC\u2011501, is being developed for X-linked retinitis pigmentosa, a severe form of inherited blindness caused by mutations in the RPGR gene.\u00a0<\/p>\n Laru\u2011zova uses an adeno-associated virus (AAV) vector to deliver a functional copy of the RPGR gene directly to photoreceptor cells via a subretinal injection. In clinical studies, the therapy has shown potential to stabilize or improve visual function in affected patients. Interim results<\/a> from the phase 1\/2 trial demonstrated sustained safety and visual improvements over 36 months. A subsequent phase 2 trial has reported<\/a> encouraging early findings, with continued assessment underway. Based on these results, Beacon launched<\/a> a registrational phase 2\/3 trial in mid-2025.\u00a0<\/p>\n A year ago, the company raised<\/a> $170 million in a series B round co-led by Forbion.\u00a0\u00a0<\/p>\n Celosia Therapeutics\u00a0<\/p>\n Celosia Therapeutics emerged from Macquarie University research in 2022 with the mission to treat neurodegenerative conditions, starting with ALS by targeting one of its core pathological drivers. The company\u2019s lead program, CTx1000, uses a viral gene therapy platform to selectively remove toxic aggregates of TDP\u201143, a protein closely linked to motor neuron degeneration in ALS. In preclinical models, CTx1000 not only halted disease progression but also showed potential to reverse established damage.\u00a0<\/p>\n Instead of targeting symptoms, CTx1000 is designed to degrade misfolded or pathological forms of TDP\u201143 while preserving its normal cellular function. The therapy leverages AAV delivery to reach both brain and spinal cord motor neurons in a one-time administration.\u00a0<\/p>\n With the closing of its $10.4 million series A<\/a> round in 2024, Celosia were aiming\u00a0for a mid-2025 start for a first-in-human trial at the time of the fundraising, and initial results are expected by 2028.\u00a0<\/p>\n Character Biosciences\u00a0<\/p>\n Character Biosciences is a precision ophthalmology company aiming to treat progressive eye diseases by tailoring therapeutics to genetically defined patient subtypes. Born out of Clover Therapeutics in 2019 and rebranded in 2022, the company draws on a rich dataset: over 6,500 AMD patients integrating genomics, imaging, and clinical data to identify molecular drivers of disease progression and refine its drug design.\u00a0<\/p>\n The company\u2019s precision platform allowed it to develop two distinct therapies for dry AMD. CTX114 is a complement-pathway inhibitor intended to slow geographic atrophy, while CTX203 is designed to modulate ABCA1 lipid transport and prevent progression in intermediate-stage AMD. Both candidates have moved into IND-enabling studies, with clinical trials expected<\/a> to start this year.\u00a0<\/p>\n In March 2025, Character secured<\/a> a $93\u202fmillion series\u202fB financing to support the launch of phase\u202f1 and 2 trials for both lead assets and support expansion into other ophthalmic genetically influenced diseases, including primary open-angle glaucoma.\u00a0<\/p>\n Genespire\u00a0<\/p>\n Genespire develops off\u2011the\u2011shelf lentiviral gene therapies designed for intravenous administration. Its immune\u2011shielded lentiviral vector (ISLV) platform is engineered to evade immune detection, enabling durable liver expression following a single dose, a promising fit for pediatric metabolic disorders like MMA, a severe genetic condition affecting amino acid and fat metabolism.\u00a0<\/p>\n GENE202, the lead asset, delivers functional methylmalonyl\u2011CoA mutase (MUT) to the liver. This aims to restore metabolic balance in MMA patients by converting lactate and amino acids correctly. Preclinical results shown<\/a> at ASGCT confirmed stable enzyme expression, reduced toxic metabolites, and strong safety data in animal models.\u00a0<\/p>\n With $52 million raised<\/a> via co\u2011lead investors Sofinnova, XGEN Venture, and CDP Venture Capital, Genespire is now preparing to initiate its phase 1\/2 clinical trial later this year.\u00a0<\/p>\n GEMMA Biotherapeutics\u00a0<\/p>\n GEMMA Biotherapeutics was founded in October 2024 by Dr. James M. Wilson, a gene therapy pioneer who previously led the Gene Therapy Program at the University of Pennsylvania. During his tenure at Penn, Wilson spearheaded research that enabled AAV vectors to become the leading delivery platform in gene therapy.\u00a0<\/p>\n The company\u2019s mission is to deliver affordable, scalable gene therapies for rare genetic diseases, especially those impacting pediatric patients and underserved communities. GEMMA uses AAV vectors and an academic-industry hybrid model, offering both its therapeutics and supporting external developers via partnerships like its $100\u202fmillion agreement<\/a> with Brazil\u2019s Fiocruz, aimed at building local manufacturing and treatment access.\u00a0<\/p>\n Although the specific therapeutic targets haven\u2019t been disclosed, GEMMA reports several \u201cactive\u201d programs in development supported by the $34 million seed funding<\/a>. These aim to address rare neurometabolic and neurodegenerative genetic disorders. Alongside a partnership with Fiocruz to potentially deploy six disease programs, GEMMA is off to a strong start.\u00a0<\/p>\n Glycomine\u00a0<\/p>\n Glycomine is a clinical-stage biotech company pioneering a novel mannose-1-phosphate (M1P) replacement therapy for PMM2-CDG, a life-threatening genetic disorder caused by enzyme deficiency in the glycosylation pathway. Its lead drug, GLM101, employs lipid nanoparticle (LNP) delivery to transport M1P into cells, bypassing PMM2 mutations. This approach restores proper glycosylation processes, a method simpler than gene editing and especially suitable for a disease that affects multiple organs.\u00a0<\/p>\n In a phase\u202f2 study, patients exhibited an average 11.9-point improvement in ataxia scores over 24\u202fweeks. Responding to that data, Glycomine raised<\/a> $115\u202fmillion in a series C round in April 2025 to launch a phase\u202f2b trial, with topline results anticipated in mid\u20112026.\u00a0<\/p>\n SpliceBio\u00a0<\/p>\n SpliceBio <\/a>is developing a novel gene therapy technique to tackle disorders caused by mutations in large genes whose size usually exceeds what standard AAV vectors can carry. Its proprietary Protein Splicing technology uses engineered inteins to split a large gene across two AAV vectors. Once inside target cells, the protein parts rejoin, enabling full-length protein function.\u00a0<\/p>\n SB\u2011007 targets Stargardt disease, a juvenile-onset macular dystrophy caused by mutations in the ABCA4 gene. The dual-AAV therapy restores functional ABCA4 protein in photoreceptors, offering potential benefit regardless of specific mutations. In December 2024, SpliceBio secured<\/a> U.S Food and Drug Administration (FDA) IND clearance, the first-ever for a dual-AAV gene therapy in Stargardt, and they later dosed the first patient in the phase\u202f1\/2 trial in March 2025.\u00a0<\/p>\n In June 2025, the biotech closed<\/a> a $135\u202fmillion series B round, bringing in EQT Life Sciences and Sanofi Ventures with participation from all existing investors, including Roche Ventures and Novartis Ventures.\u00a0\u00a0<\/p>\n SpliceBio\u2019s platform overcomes a fundamental limitation in gene therapy: the payload capacity of AAV. It potentially offers a scalable way to address large gene disorders.\u00a0\u00a0<\/p>\n Vico Therapeutics\u00a0<\/p>\n Vico Therapeutics is focused on antisense oligonucleotide (ASO) therapies<\/a> for severe neurological disorders driven by CAG-repeat expansions, most notably Huntington\u2019s disease<\/a>, spinocerebellar ataxias 1 and 3 (SCA1\/SCA3).\u00a0<\/p>\n Its lead program, VO659, employs an allele-preferential mechanism: it selectively binds mRNA transcripts with expanded CAG repeats common to polyglutamine diseases, reducing mutant protein levels while sparing the normal allele. In a phase\u202f1\/2a trial initiated in 2023, patients dosed with VO659 showed<\/a> an average 28% reduction in CSF mutant huntingtin protein, a biomarker of neuronal injury.\u00a0<\/p>\n Genetic disease-focused biotech companies are maturing\u00a0<\/p>\n\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n